Latest news with #AliRezaie
Yahoo
05-05-2025
- Health
- Yahoo
mBIOTA Elemental™ Effectively Reduces IMO-Causing Methanogenic Archaea M. smithii
Featured oral presentation at Digestive Disease Week 2025 demonstrates significant modulatory effects of palatable elemental diet on methanogens in managing the gut microbiome beyond just bacteria SANTA MONICA, Calif., May 05, 2025--(BUSINESS WIRE)--mBIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) conditions, announces that their flagship product, mBIOTA Elemental™ Diet, has shown effectiveness at managing the gut microbiome beyond just gut bacteria. The first clinically-proven palatable elemental diet, initially studied as a solution for small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) as focused on reducing intestinal bacteria and related symptoms of such gastrointestinal disorders, has now been demonstrated to effectively reduce Methanobrevibacter smithii (M. smithii), an abundant methane-producing archaea in humans that is known to cause IMO. Prospective clinical trial data measuring the presence of M. smithii in individuals with IMO via methane breath testing and stool samples demonstrated a statistically significant decrease in methanogenic archaea. Detected in 61% of participants with IMO at the baseline, M. smithii was either decreased or undetectable in 92% of participants by the end of the study. These findings, as featured at Digestive Disease Week (DDW) 2025 in an oral presentation titled "Reduction Of Breath Methane Levels Correlates With Fecal Abundance Of Methanobrevibacter Smithii Following Two-Weeks Of Exclusive Oral Elemental Diet," expand upon promising medical use cases of mBIOTA Elemental™ for the management of GI conditions. "The gut microbiome is filled with more microorganisms than just bacteria. Archaea also play a significant role in how the human gut functions and the gastrointestinal symptoms individuals may experience, such as constipation," says Dr. Ali Rezaie, medical advisor to mBIOTA Labs and renowned gastroenterologist. "While more research is needed to determine the long-term effects of elemental diet in individuals with IMO, these findings are encouraging for the development of a more targeted solution to manage excess gut archaea." "mBIOTA Labs has made great strides in increasing the accessibility of elemental diets by focusing on improving palatability and reinforcing the clinical proof behind mBIOTA Elemental™ for managing the gut microbiome as a whole with peer-reviewed studies. We're glad to continue the trend with these new positive findings for archaea modulation," says Nicola Wodlinger, CEO of mBIOTA Labs. "We're dedicated to offering providers a tool for their patients that targets the root causes of GI conditions to optimize gut health rather than temporarily treating the symptoms. This is one huge step forward for helping IMO patients." mBIOTA Labs' truly palatable elemental diet offers patients an approachable and clinically reliable option to manage GI conditions like SIBO and IMO. For more information on mBIOTA Labs, mBIOTA Elemental™, and related clinical findings, visit About mBIOTA Labs mBIOTA Labs harnesses proprietary Amino Taste Modification Technology (ATMT) to create clinically proven, science-backed medical foods, designed to optimize gut health and overall well-being. Trusted by the medical community, mBIOTA's mission is to empower individuals with evidence-based nutrition solutions that enhance quality of life. mBIOTA's award-winning, clinically proven, palatable elemental diet, mBIOTA Elemental™, revolutionizes medical nutrition for the dietary management of GI dysfunction, including small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), intestinal methanogen overgrowth (IMO), eosinophilic esophagitis (EoE) and other conditions. For more information on mBIOTA Labs and mBIOTA Elemental™, visit View source version on Contacts Media Contact:Sarah BrowningPublic Relations for mBIOTA Labsmbiota@
Business Wire
05-05-2025
- Health
- Business Wire
mBIOTA Elemental™ Effectively Reduces IMO-Causing Methanogenic Archaea
SANTA MONICA, Calif.--(BUSINESS WIRE)-- mBIOTA Labs, an emerging medical food company revolutionizing medical nutrition for the management of gastrointestinal (GI) conditions, announces that their flagship product, mBIOTA Elemental™ Diet, has shown effectiveness at managing the gut microbiome beyond just gut bacteria. The first clinically-proven palatable elemental diet, initially studied as a solution for small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) as focused on reducing intestinal bacteria and related symptoms of such gastrointestinal disorders, has now been demonstrated to effectively reduce Methanobrevibacter smithii (M. smithii), an abundant methane-producing archaea in humans that is known to cause IMO. Prospective clinical trial data measuring the presence of M. smithii in individuals with IMO via methane breath testing and stool samples demonstrated a statistically significant decrease in methanogenic archaea. Detected in 61% of participants with IMO at the baseline, M. smithii was either decreased or undetectable in 92% of participants by the end of the study. These findings, as featured at Digestive Disease Week (DDW) 2025 in an oral presentation titled 'Reduction Of Breath Methane Levels Correlates With Fecal Abundance Of Methanobrevibacter Smithii Following Two-Weeks Of Exclusive Oral Elemental Diet,' expand upon promising medical use cases of mBIOTA Elemental™ for the management of GI conditions. 'The gut microbiome is filled with more microorganisms than just bacteria. Archaea also play a significant role in how the human gut functions and the gastrointestinal symptoms individuals may experience, such as constipation,' says Dr. Ali Rezaie, medical advisor to mBIOTA Labs and renowned gastroenterologist. 'While more research is needed to determine the long-term effects of elemental diet in individuals with IMO, these findings are encouraging for the development of a more targeted solution to manage excess gut archaea.' 'mBIOTA Labs has made great strides in increasing the accessibility of elemental diets by focusing on improving palatability and reinforcing the clinical proof behind mBIOTA Elemental™ for managing the gut microbiome as a whole with peer-reviewed studies. We're glad to continue the trend with these new positive findings for archaea modulation,' says Nicola Wodlinger, CEO of mBIOTA Labs. 'We're dedicated to offering providers a tool for their patients that targets the root causes of GI conditions to optimize gut health rather than temporarily treating the symptoms. This is one huge step forward for helping IMO patients.' mBIOTA Labs' truly palatable elemental diet offers patients an approachable and clinically reliable option to manage GI conditions like SIBO and IMO. For more information on mBIOTA Labs, mBIOTA Elemental™, and related clinical findings, visit About mBIOTA Labs mBIOTA Labs harnesses proprietary Amino Taste Modification Technology (ATMT) to create clinically proven, science-backed medical foods, designed to optimize gut health and overall well-being. Trusted by the medical community, mBIOTA's mission is to empower individuals with evidence-based nutrition solutions that enhance quality of life. mBIOTA's award-winning, clinically proven, palatable elemental diet, mBIOTA Elemental™, revolutionizes medical nutrition for the dietary management of GI dysfunction, including small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), intestinal methanogen overgrowth (IMO), eosinophilic esophagitis (EoE) and other conditions. For more information on mBIOTA Labs and mBIOTA Elemental™, visit
New York Post
30-04-2025
- Health
- New York Post
Is it really IBS? This lesser-known stomach issue is often misdiagnosed and can cause nausea and toilet problems
You shouldn't have to stomach a constantly upset stomach. Bloating, gas and discomfort are often dismissed as harmless digestive issues, but they can sometimes signal more serious health problems. 'Normalizing chronic symptoms like bloating, discomfort or irregular bowel habits can delay diagnosis of underlying conditions such as SIBO, IBS, celiac disease or even inflammatory bowel disease and colon cancer,' Dr. Ali Rezaie, medical director of the GI Motility Program at Cedars-Sinai in LA, told The Post. 3 More than half (51%) of Americans think stomach issues such as bloating, gas and discomfort are 'normal.' Daniel – If you're wondering what Rezaie means when he says 'SIBO,' you're not alone. A recent survey revealed that three out of four Americans have never heard of SIBO, and — of those diagnosed with irritable bowel syndrome (IBS) — 41% said their healthcare provider never mentioned SIBO as a possible cause of their symptoms. The gut disorder is often misdiagnosed as IBS. 'SIBO stands for small intestinal bacterial overgrowth, a condition where excess or misplaced bacteria in the small intestine lead to GI symptoms including post-prandial bloating, distention, gas, abdominal pain, diarrhea and/or constipation,' Rezaie explained. 'People with IBS, diabetes, prior abdominal surgery or conditions that slow gut motility — like scleroderma — are at higher risk' of SIBO. SIBO has been historically underrecognized, Rezaie said, due to limitations in medical training and diagnostic tools. 'Until recently, symptoms like bloating were often lumped into general IBS without exploring microbial causes. As research grows, awareness is increasing — but gaps still persist,' he said. A similar condition, intestinal methanogen overgrowth (IMO), involves methane-producing bugs and causes many of the same miserable symptoms. 3 Small intestinal bacterial overgrowth (SIBO) is often misdiagnosed as irritable bowel syndrome. methaphum – For those diagnosed with SIBO, one promising treatment option is the elemental diet — a bland but scientifically-backed protocol that nourishes you while starving the unruly bacteria to reduce overgrowth. 'It's a liquid nutrition plan with pre-digested nutrients that are absorbed in the upper small intestine,' Rezaie said. You may be tempted to pop some popular probiotics, but he cautions they may do more harm than good. Probiotics can worsen SIBO or IMO symptoms by adding more bacteria to an already overpopulated intestine, Rezaie said. 'Some experience more bloating or brain fog,' he continued. 'Probiotics should be personalized — not assumed safe for everyone.' 3 'SIBO has historically been underrecognized due to limited training in medical education and a lack of widespread diagnostic tools,' Dr. Ali Rezaie said. Witoon – So, why are gut issues blooming in the first place? Blame the 21st-century lifestyle. 'Highly processed diets, food additives, sedentary lifestyles and increased gut infections contribute to reduced microbial diversity and gut dysfunction,' Rezaie said. 'Our modern habits have outpaced what the microbiome evolved to handle.' His prescription for prevention is refreshingly old-school. 'Eat a diverse, whole-foods diet, minimize processed foods, stay active, sleep well and don't ignore chronic symptoms — early care can make a big difference,' he advised. Unfortunately, the new survey found that 27% of patients feel dismissed when they raise concerns about chronic gut issues to their doctor. 'Providers need to listen more carefully and avoid labeling symptoms as 'just stress' or 'normal,'' Rezaie said. 'Validating patient concerns, asking detailed questions and staying updated on research is key,' he added. 'When patients feel heard, they're more likely to engage in effective treatment.'
